Press Releases Daiichi Sankyo Company, Limited

Stocks

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 15/07/2026 pm IST			5-day change	1st Jan Change
2,677.00 ^JPY	-0.09%		-1.47%	-20.04%

08/07	European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites	MT
08/07	AstraZeneca and Daiichi near UK Enhertu price deal - Bloomberg	AN

Press Releases

30/06	AstraZeneca - Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours	AQ
29/06	Daiichi Sankyo - Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	AQ
29/06	Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	BU
26/06	Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy	BU
24/06	Daiichi Sankyo Europe Pfaffenhofen Plant (Germany) has obtained ISO45001:2018 certification	PU
19/06	Daiichi Sankyo : Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF	PU
15/06	Daiichi Sankyo : Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML	PU
09/06	Daiichi Sankyo : Selected as SX Brand for the Third Consecutive Year	PU
29/05	Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta® in Newly Diagnosed FLT3-ITD Positive AML	AQ
28/05	Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO	BU
26/05	Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026	BU
22/05	Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates	BU
22/05	Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors	BU
20/05	Daiichi Sankyo : Participation in WHO-GBCI Phase 2 through a Partnership with City Cancer Challenge (C/Can) — Contributing to Breast Cancer Care in Low- and Middle-Income Countries	PU
16/05	Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer	BU
11/05	Daiichi Sankyo : Presentation MaterialPDF	PU
11/05	Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation	BU
08/05	Daiichi Sankyo : Announces Occurrence of Losses Related to Review of Product Supply Plans and Revision of Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026	PU
08/05	Daiichi Sankyo : Listed on the Dow Jones Best-in-Class Asia Pacific Index	PU
08/05	Daiichi Sankyo : Presentation Material PDF	PU
24/04	Daiichi Sankyo Announces Rescheduling of the Announcement of Consolidated Financial Results for Year Ended March 31, 2026	AQ
16/04	Daiichi Sankyo : Announces Appointment of Chief Corporate Affairs Officer under the Global Management Structure	PU
27/03	Daiichi Sankyo : ENHERTU® Followed by THP Approved in China as the First and Only HER2 Directed ADC for the Neoadjuvant Treatment of HER2 Positive Breast Cancer	PU
25/03	Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program	BU
25/03	Daiichi Sankyo : Announces Rescheduling of 5-year Business Plan (FY2026 - FY2030) Presentation & Discussion	PU